Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 7/20 | 0.58 |
| ▸ | STIM1 | Q13586 | 7/20 | 0.58 |
| ▸ | ORAI1 | Q96D31 | 7/20 | 0.58 |
| ▸ | TNF | P01375 | 1/20 | 0.58 |
| ▸ | ESRRG | P62508 | 3/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2728138 | 0.88 | STIM1 (0.49) | IL2STIM1ORAI1TNFESRRG | |
| SCHEMBL2731604 | 0.86 | IL2 (0.63) | IL2STIM1ORAI1TNFESRRG | |
| SCHEMBL15205665 | 0.86 | IL2 (0.55) | IL2STIM1ORAI1TNFESRRG | |
| SCHEMBL15528202 | 0.85 | STIM1 (0.53) | IL2STIM1ORAI1TNFESRRG | |
| SCHEMBL2732760 | 0.83 | IL2 (0.58) | IL2STIM1ORAI1TNFESRRG | |
| SCHEMBL2733154 | 0.83 | IL2 (0.52) | IL2STIM1ORAI1TNFESRRG | |
| SCHEMBL15528238 | 0.81 | IL2 (0.49) | IL2STIM1ORAI1TNFESRRG | |
| SCHEMBL15528586 | 0.81 | IL2 (0.50) | IL2STIM1ORAI1TNFESRRG | |
| SCHEMBL15528184 | 0.81 | STIM1 (0.48) | IL2STIM1ORAI1TNFESRRG | |
| SCHEMBL15204992 | 0.80 | IL2 (0.49) | IL2STIM1ORAI1TNFESRRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170304299-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | LUPIN LTD (IN) | 2017-10-26 | — | — | US | claimed |
| EP-3067347-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | Lupin Limited (IN) | 2016-09-14 | — | — | EP | claimed |
| EP-2632906-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | Lupin Limited (IN) | 2013-09-04 | — | — | EP | claimed |
| US-20130225600-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2013-08-29 | — | — | US | claimed |
| WO-2012056478-A1 | OXAZOLE AND ISOXAZOLE CRAC MODULATORS | LUPIN LIMITED (IN) | 2012-05-03 | — | — | WO | claimed |
| US-10292981-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2019-05-21 | — | — | US | disclosed |
| US-10292981-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2019-05-21 | — | — | US | disclosed |
| US-20170304299-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | LUPIN LTD (IN) | 2017-10-26 | — | — | US | disclosed |
| US-20170304299-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | LUPIN LTD (IN) | 2017-10-26 | — | — | US | disclosed |
| US-9737534-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-22 | — | — | US | disclosed |
| US-9737534-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-22 | — | — | US | disclosed |
| EP-3067347-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | Lupin Limited (IN) | 2016-09-14 | — | — | EP | disclosed |
| EP-3067347-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | Lupin Limited (IN) | 2016-09-14 | — | — | EP | disclosed |
| US-20160022673-A1 | OXAZOLE AND ISOXAZOLE CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-01-28 | — | — | US | disclosed |
| US-20160022673-A1 | OXAZOLE AND ISOXAZOLE CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-01-28 | — | — | US | disclosed |
| US-9169242-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2015-10-27 | — | — | US | disclosed |
| US-9169242-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2015-10-27 | — | — | US | disclosed |
| US-20130225600-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022673-A1 | OXAZOLE AND ISOXAZOLE CRAC MODULATORS | RYR2, RYR1, GABRR1 | IL2 2413/4885STIM1 33/4885ORAI1 10/4885 |
| US-10292981-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | RYR2, RYR1, ADRA2C | IL2 3012/4885STIM1 69/4885ORAI1 13/4885 |
| US-20170304299-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | RYR2, ADRA2C, RYR1 | IL2 2980/4885STIM1 76/4885ORAI1 14/4885 |
| US-20130225600-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | RYR2, ADRA2C, RYR1 | IL2 2980/4885STIM1 76/4885ORAI1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.